MRP Capital Investments LLC Acquires 4,975 Shares of Solventum Co. (NYSE:SOLV)

MRP Capital Investments LLC increased its holdings in Solventum Co. (NYSE:SOLV) by 93.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,275 shares of the company’s stock after purchasing an additional 4,975 shares during the quarter. MRP Capital Investments LLC’s holdings in Solventum were worth $679,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Investment House LLC lifted its holdings in shares of Solventum by 111.3% during the fourth quarter. Investment House LLC now owns 76,171 shares of the company’s stock valued at $5,032,000 after purchasing an additional 40,130 shares during the last quarter. Xponance Inc. raised its holdings in Solventum by 9.8% in the 4th quarter. Xponance Inc. now owns 21,014 shares of the company’s stock worth $1,388,000 after acquiring an additional 1,879 shares during the last quarter. Boston Partners purchased a new position in Solventum in the 4th quarter worth approximately $110,378,000. Generali Asset Management SPA SGR purchased a new position in Solventum in the 4th quarter worth approximately $659,000. Finally, Thrivent Financial for Lutherans raised its holdings in Solventum by 37.9% in the 4th quarter. Thrivent Financial for Lutherans now owns 12,721 shares of the company’s stock worth $863,000 after acquiring an additional 3,498 shares during the last quarter.

Solventum Stock Down 1.7 %

Shares of SOLV stock opened at $74.98 on Friday. The stock has a market cap of $12.97 billion and a P/E ratio of 27.27. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. The company’s fifty day simple moving average is $75.04 and its two-hundred day simple moving average is $71.44.

Analyst Upgrades and Downgrades

A number of research firms have commented on SOLV. Mizuho lifted their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. Morgan Stanley boosted their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 5th. Piper Sandler boosted their price objective on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research report on Friday, February 28th. Wells Fargo & Company boosted their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Finally, Bank of America upped their target price on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, Solventum presently has a consensus rating of “Hold” and a consensus target price of $79.86.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.